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Abstract
Leprosy is a chronic progressive granulomatous disease that caused by Mycobacterium leprae, an intracellular 
obligate bacteria. Leprosy can be treated using multidrug therapy (MDT) that can be associated with hepatotoxicity 
as their side effects. We included 14 patients that were all diagnosed with multibacillary leprosy, but with four drops 
out persons. Liver function evaluations before MDT were in the normal range. After 1st, 2nd, and 3rd months of MDT, 
liver function test in research subjects also in the normal range even though there is variation in this value. There 
is a risk of hepatotoxicity of MDT; therefore, liver function test should be done periodically for early detection of any 
liver dysfunction.
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Introduction
Leprosy is a chronic progressive granulomatous 
disease that caused by Mycobacterium leprae, an 
intracellular obligate bacteria [1]. Leprosy can affect 
peripheral nerve and skin and other organs except central 
nervous system [1], [2], [3]. This disease is endemic in 
many tropical and subtropical countries, including Brazil, 
India, and Indonesia. These countries contribute to 82% 
of new leprosy cases globally [4], [5], [6].
In 2014, there are 17.025 new leprosy cases 
reported from Indonesia and 83.5% of these cases 
were classified as multibacillary (MB) leprosy, whereas 
according to gender, 62.6% of leprosy patients were 
male and 37.4% were female [3]. According to the 
prevention and control of tropical disease in Indonesia 
on 2017, there were 15.910 new leprosy cases in 
Indonesia, and 158 of these cases can be found in 
North Sumatera Province. Data of new leprosy patients 
according to the medical record of Haji Adam Malik 
General Hospital Medan in 2015, are 16 cases, 2016, 
with 19 cases and 2017 with 14 cases.
According to the WHO, leprosy can be 
classified into paucibacillary (PB) and MB type [7]. 
Leprosy can be treated using multidrug therapy (MDT), 
a combination of two or more anti-leprosy drug such as 
rifampicin, dapsone, and clofazimine. Rifampicin and 
dapsone are the most important medication that given 
to both PB and MB leprosy [8]. Metabolism of rifampicin 
and dapsone are both occur in the liver, include 
hydroxylation and oxidation by cytochrome P450 
enzyme [9], [10]. However, research by Dhavalshankh 
et al. describe that liver function dysfunction can be 
found in leprosy patient even before MDT [11].
Swathi in India reported that there were 
significant differences in total protein serum between 
the case and control group [1]. The result of a study by 
Bjornsso in Sweden found that 22.9% subjects showed 
an increase of bilirubin more than 2 times of normal 
value and more than 3 times increase of alanine 
transaminase (ALT) [12]. Research by Tsankov and 
Kamashev in Bulgaria concluded that hepatotoxicity 
of the earliest complication can be found from 
rifampicin [13].
There are several parameters that can be 
used to detect liver dysfunction such as total bilirubin 
serum level, ALT, aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), total protein, albumin, and 
globulin [1], [8], [14]. Evaluation of liver function is carried 
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out every 4 weeks for 3 months of medication [1], [15], [16]. 
If there is an increase of more than 2–3 times the normal 
limit, the medication can be stopped temporarily and the 
patient should be monitored [15].
Until now, research on leprosy medication 
and its side effect in Indonesia, especially in North 
Sumatera, is still very limited, while MDT is still part of 
the Ministry of Health Republic of Indonesia Program to 
manage and eradicate leprosy. Therefore, we wanted 
to analyze the liver function test before and after MDT 
in 3 months on leprosy patients in Haji Adam Malik 
General Hospital Medan.
Methods
This is descriptive research with case series 
on all leprosy patients that came to Leprosy Division 
in Dermatology and Venereology Department of Haji 
Adam Malik General Hospital Medan from January 
to December 2017. Liver function tests were done in 
the Clinical Pathology Laboratory of Haji Adam Malik 
General Hospital Medan. Inclusion criteria are include 
new leprosy patient that diagnosed with PB and MB 
leprosy that has not been treated with MDT; agree to 
be included in this research by signing the informed 
consent; age between 18 and 60 years old. Exclusion 
criteria include pregnancy; a patient that consumes 
systemic medication of other diseases or other 
hepatotoxic medication; a patient that stopped taking 
MDT; chronic alcohol consumption; and had a history of 
jaundice and other liver diseases.
Research subjects who had signed the 
informed consent form were had their blood taken for 
liver function test, which include total bilirubin serum, 
ALT, AST, ALP, total protein, albumin, and globulin 
before MDT. These subjects were then had their 
blood taken again for another liver function test after 
1, 2, and 3 months of MDT. The data were collected 
and analyzed using statistical software. A descriptive 
analysis was carried out to determine the mean and 
standard deviation value of variables that were studied. 
This research was carried out after obtained ethical 
clearance from the Research Ethics Committee of 
Faculty of Medicine, Universitas Sumatera Utara.
Results
There were 14 patients that were included in 
this research and all of them were diagnosed as MB 
leprosy, but there were four drops out persons. The 
majority of these patients were male (70%) and there 
were six subjects that age more than 30 years old. Blood 
AQ5
examination for liver function before MDT showed a 
normal mean value of total bilirubin, ALP, ALT, AST, total 
protein, and albumin, whereas mean value of globulin 
was higher than its normal range.
Table 1: Sex and age characteristics of leprosy patients
Characteristics Leprosy patients
n (%)
Gender
Male 7 70.0
Female 3 30.0
Age
≤20 3 30.0
21–30 3 30.0
3–40 2 20.0
≥40 2 20.0
Highest bilirubin level was found after 1 month 
of MDT with 0.61 mg/dl (SD = 0.28 mg/dl). Lowest 
bilirubin level was found before MDT with 0.43 mg/dl 
(SD = 0.22 mg/dl). The highest level of ALT was found 
after 1 month of MDT with 33 U/L (SD = 32.52 U/L), 
while the lowest level was seen after 3 months of 
MDT with 17.4 U/L (SD = 6.7 U/L). The highest level 
of AST was seen after 1 month of MDT with 30.5 U/L 
(SD = 21.96 U/L) and the lowest level was seen after 
3 months with 22.2 U/L (SD=4.47 U/L).
Table 2: Liver function test in leprosy patient with MDT 
medication
Liver function 
test
Before MDT After 1 
month
After 2 
months
After 3 
months
Total bilirubin 0.43±0.22 0.81±0.54 0.61±0.28 0.63±0.24 mg/dl
ALT 22.7±14.61 33±32.52 24.6±19.78 17.4±6.7 U/L
AST 25.1±12.27 30.5±21.96 22.4±8.03 22.2±4.47 U/L
ALP 78±28.04 95.7±56.47 68.6±21.37 67.4±22.33 U/L
Total protein 7.89±1.29 7.67±1.31 7.49±1.22 7.72±1.29 g/dL
Albumin 3.66±0.75 3.62±0.59 3.68±0.79 3.89±0.64 g/dL
Globulin 4.23±1.79 4.05±1.63 3.81±1.84 3.84±1.67 g/dL
MDT: Multidrug therapy, ALT: Alanine transaminase, AST: Aspartate aminotransferase, ALP: Alkaline 
phosphatase.
The highest level of ALP was seen after 
1 month of MDT with 95.7 U/L (SD = 56.47 U/L) and the 
lowest was found after 3 months of MDT with 67.4 U/L 
(SD = 22.33 U/L). Total protein was the highest before 
MDT with 7.89 g/dl (SD = 1.29 g/dl), but the lowest 
was seen after 2 months of medication with 7.49 g/dl 
(SD = 1.22 g/dl).
Albumin was highest at 3 months after 
medication with 3.89 g/dl (SD = 0.64 g/dl) and the 
lowest was found after 1 month of MDT with 3.62 g/dl 
(SD = 0.59 g/dl). The highest level of globulin was seen 
before medication with 4.23 g/dl (SD = 1.79 g/dl), while 
the lowest level of globulin was found after 3 months of 
MDT with 3.81 g/dl (SD = 1.84 g/dl).
Discussion
This research involved 14 research patients 
with the majority of male and age <30 years old. Data 
from Indonesia also showed that leprosy is often seen 
in male than female [3]. According to a study by Moet 
et al., age and gender are risk factors of leprosy. This 
probably happens because male has more interaction 
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with other people due to work, therefore, more prone 
to infection than female [17], [18]. Besides, we did not 
identify any side effects of MDT in all subjects.
Liver function evaluations before MDT were 
in the normal range. An increase in transaminase 
serum level usually seen in lepromatous leprosy type 
patients [19], whereas in patients with borderline and 
tuberculoid type usually show normal ALT, AST, and 
ALP level [20]. Several research showed an increase 
of bilirubin serum in lepromatous type. Dhavalshankh 
et al. found that bilirubin level did not increase 
significantly in multibacillary and paucibacillary type 
leprosy. However, there is an increase in mean globulin 
value compared to its normal range. This research 
also showed that patients with multibacillary leprosy 
had a significant decrease of albumin level, but it is not 
significant in globulin level [11]. Most globulin protein 
is produced by the liver; however, globulin in the form 
of immunoglobulins is produced by plasma cells [21]. 
This can affect globulin levels from the research 
subject.
Medication using MDT in leprosy patients can 
cause abnormal liver function, which usually caused by 
Rifampicin and Dapsone [22]. Research by Deps et al. 
showed abnormality of liver function that caused by 
Dapsone can be seen in 20 of 85 patients, whereas 
rifampicin consumption caused abnormal liver function 
in 10 out of 24 research subjects [21]. Other reports 
showed that rifampicin is causing hepatotoxicity in <1% 
patients [23].
In research subjects, laboratory examination in 
the 1st, 2nd, and 3rd months after MDT showed normal 
liver function even though there is variation in this 
value. The majority of patients can tolerate the side 
effects of rifampicin and dapsone with appropriate 
dosage [13], [24], [25]. However, evaluation of liver 
function still needs to be done to identify an abnormal 
liver function as early as possible [23].
Conclusion
The current research showed a normal liver 
function test before MDT, which includes total bilirubin 
serum, ALT, AST, ALP, total protein, albumin, and 
globulin. Moreover, there is no difference between 
liver function test after 1 month, 2 months, and 
3 months of MDT in leprosy patients in Haji Adam Malik 
General Hospital Medan. However, there is a risk of 
hepatotoxicity of MDT; therefore, we advised doing liver 
function tests periodically for early detection of any liver 
dysfunction.
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